Skip to main content

Table 2 Measures of agreement between selected OCR-based and POGONIS-based diagnostic subgroups

From: The validity of pediatric cancer diagnoses in a population-based general cancer registry in Ontario, Canada

Malignancy type N, POGONIS N, OCR Kappa (95 % CI) Sensitivity Specificity PPV NPV
Ia.1. Precursor cell leukemias (acute lymphoblastic leukemia) 1070 775 0.77 (0.75–0.80) 0.71 0.99 0.98 0.91
Ib. Acute myeloid leukemias 187 164 0.84 (0.81–0.89) 0.80 1.00 0.91 0.99
IIa. Hodgkin lymphomas 312 310 0.99 (0.98–1.00) 0.98 1.00 0.99 1.00
IIb-IId, IIe. Non Hodgkin lymphomas 271 244 0.78 (0.74–0.82) 0.76 0.99 0.84 0.98
IIb.1 Precursor cell lymphomas (lymphoblastic lymphomas) 67 22 0.24 (0.12–0.36) 0.16 1.00 0.50 0.99
IIc. Burkitt lymphomas 78 1 0.02 (0.02–0.07) 0.01 1.00 1.00 0.98
IIIb. Astrocytomas 446 343 0.82 (0.79–0.85) 0.74 1.00 0.96 0.97
IIIa1. Ependymomas 72 69 0.95 (0.91–0.99) 0.93 1.00 0.97 1.00
IIIc. Intracranial and intraspinal embryonal tumors 199 201 0.91 (0.87–0.94) 0.91 1.00 0.91 1.00
IIIc.1 Medulloblastomas 152 134 0.91 (0.88–0.95) 0.86 1.00 0.98 1.00
IIIx. All other CNS tumors 73 144 0.34 (0.26–0.43) 0.53 0.97 0.27 0.99
IVa. Neuroblastoma and ganglioneurblastoma 259 254 0.97 (0.96–0.99) 0.97 1.00 0.98 1.00
VIa.1 Nephroblastoma 141 140 0.98 (0.97–1.00) 0.98 1.00 0.99 1.00
VIIa. Hepatoblastoma 58 56 0.96 (0.93–1.00) 0.95 1.00 0.98 1.00
VIIIa. Osteosarcoma 88 87 0.96 (0.93–0.99) 0.95 1.00 0.97 1.00
VIIIc. Ewing tumor and related sarcomas of bone 82 93 0.81 (0.74–0.87) 0.87 0.99 0.76 1.00
IXa. Rhabdomyosarcomas 116 128 0.92 (0.89–0.96) 0.97 1.00 0.88 1.00
IXb-IXe. Non-rhabdomyosarcoma soft tissue sarcomas 153 132 0.71 (0.65–0.77) 0.67 0.99 0.78 0.99
  1. CI confidence interval, CNS central nervous system, N number, NPV negative predictive value, OCR Ontario Cancer Registry, POGONIS Pediatric Oncology Group of Ontario Networked Information System, PPV positive predictive value